Shots:

• The partnership will utilize Novogene's molecular diagnostics capabilities to expand patient identification by NGS in China for supporting the development of Hummingbird's HMBD-001 which is expected to enter P-I study in 2021 to treat NRG1-fusion driven cancers
• The partnership focuses on validation and expansion of clinical-grade testing for NRG1 fusions in patient populations with selected solid tumors
• The pre-clinical studies showed that the therapy potently inhibits the formation of heterodimers- blocking the activation of signaling pathway and prevents tumor growth

  | Ref: PR Newswire | Image: PR Newswire